 All study participants will be premedicated with oral dexamethasone, 16 mg per day e.g. 8 mg b.i.d. for three days, starting one day prior to each study drug infusion, in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. During each treatment cycle, both the test and the reference treatments will receive identical dosages of docetaxel i.e., 75 mgm2, by i.v. infusion, over 1 hour. 